Compare Dover Corp (DOV) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dover Corp vs State Street SPDR S&P Biotech ETF — how do they compare? Dover Corp trades at $210.35 (market cap $28.84B), while State Street SPDR S&P Biotech ETF trades at $155.28. The key difference: Dover Corp pays a 0.97% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Dover Corp nearer its low. Which is the better fit depends on your goals.
| DOV | XBI | |
|---|---|---|
Market Cap | $28.84B | — |
Sector | Industrials | Broad Market / Factor |
52-Week High | $233.31 | $164.28 |
52-Week Low | $161.16 | $85.16 |
Enterprise Value | $30.49B | — |
Dividend Yield | 0.97% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dover Corporation (DOV) trades at $214.27, down 0.49% on the day, with a bearish technical signal and neutral oscillators. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS expected at $2.72. Financials show solid profitability with a 13.3% net income margin and 15.06% ROE, though cash flow turned negative in 2025. Recent news highlights product launches in fueling solutions and data center technologies, indicating ongoing innovation.
The outlook is mixed: strong analyst consensus (64% buy ratings) and a $250.67 price target suggest upside, but bearish technicals and negative net cash flow pose near-term risks. Investors should weigh robust fundamentals against market volatility and execution challenges in a competitive industrial sector.
XBI trades at $155.34, down 2.32% on the day, but maintains a bullish technical outlook with strong momentum indicators. The biotech ETF has gained significant attention after a 17% monthly surge, driven by sector rotation and M&A activity. Analyst coverage remains limited with a single hold rating, though recent news highlights biotech's strong performance amid market volatility.
The ETF offers exposure to biotech's resurgence with AI drug discovery and deal momentum as catalysts. However, high volatility and concentrated sector risk require careful position sizing. Current technical strength suggests potential for continued upside if sector momentum persists.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Dover Corp
Dover is a diversified industrial manufacturing company with products and services that include digital printing for fast-moving consuming goods, marking and coding for the food and beverage industry, loaders for the waste collection industry, pumps for the transport of fluids, including petroleum and natural gas, and commercial refrigerators used in groceries and convenience stores. Most of the business operates in the United States. After the spinoff of Apergy, the company operates through five segments: engineered systems, clean energy and fueling solutions, imaging and identification, pumps and process solutions, and climate and sustainability technologies equipment.
Read more on DOV →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
